Karyopharm announces $165 million private placement

Newton, mass. , dec. 5, 2022 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has entered into a securities purchase agreement with certain institutional investors for a private placement that is expected to result in gross proceeds of approximately $165 million before deducting any offering related expenses.
KPTI Ratings Summary
KPTI Quant Ranking